About Nexus BioQuest
Nexus BioQuest is a company based in London (United Kingdom) founded in 2022. Nexus BioQuest has raised $5.21 million across 3 funding rounds. Nexus BioQuest offers products and services including Drug Discovery Services, Bespoke Assay Design, and Drug Discovery Tool. Nexus BioQuest operates in a competitive market with competitors including Anabios, Metrion Biosciences, Quiver Bioscience, Antibody Analytics and Zen-Bio, among others.
- Headquarter London, United Kingdom
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nexus Bioquest Limited
- Date of Incorporation 25 May, 2022
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.21 M (USD)
in 3 rounds
-
Latest Funding Round
$4.38 M (USD), Seed
Jul 27, 2022
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nexus BioQuest
Nexus BioQuest offers a comprehensive portfolio of products and services, including Drug Discovery Services, Bespoke Assay Design, and Drug Discovery Tool.
Comprehensive assays for target validation and candidate selection in immunology.
Tailored immunological study design for complex research questions.
Platform to select immune assays for specific therapeutic areas.
People of Nexus BioQuest
Unlock access to complete
Senior Team
4 people
Principal Team
4 people
Scientist Team
2 people
Leadership Team
2 people
Lead Team
2 people
Unlock access to complete
Funding Insights of Nexus BioQuest
Nexus BioQuest has successfully raised a total of $5.21M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $4.38 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Nexus BioQuest
Investment portfolio details for Nexus BioQuest
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nexus BioQuest
Detailed financials for Nexus BioQuest
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nexus Bioquest Comparisons
Peer comparison for Nexus BioQuest
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nexus BioQuest
Nexus BioQuest operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Anabios, Metrion Biosciences, Quiver Bioscience, Antibody Analytics and Zen-Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ex-vivo human tissue studies are performed for preclinical drug discovery.
|
|
| Locked | Locked | Locked |
Ion channel screening and cardiac safety profiling services are provided.
|
|
| Locked | Locked | Locked |
Developer of transformational medicines for neurological disorders
|
|
| Locked | Locked | Locked |
Antibody analytics and characterization services are provided.
|
|
| Locked | Locked | Locked |
Cell-based solutions are provided to accelerate therapy discovery and development.
|
|
| Locked | Locked | Locked |
Drug-target interactions are quantified via specialized assay services.
|
Detailed competitors of Nexus BioQuest
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nexus Bioquest
Complete news archive for Nexus BioQuest
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nexus BioQuest
Nexus BioQuest was founded in 2022.
Nexus BioQuest is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Nexus BioQuest is a funded company, having raised a total of $5.21M across 3 funding rounds to date.
Nexus BioQuest was founded in 2022 in London, United Kingdom. Services in drug discovery are delivered by the company within the biotechnology sector. Core operations encompass target validation, compound screening, and lead optimization to aid pharmaceutical development. Clients in the life sciences industry are supported through these specialized processes, with activities based in the UK.
Nexus BioQuest's top competitors include Metrion Biosciences, Quiver Bioscience and Anabios.
Nexus BioQuest offers Drug Discovery Services, Bespoke Assay Design, and Drug Discovery Tool.